Is the price fair?
What IART's price assumes
Today's price asks for 45% free cash flow growth a year; over the last three years Integra LifeSciences Holdings Corporation delivered −73%, the price is ahead of the record.
0.44
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.30%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +45%
Growth the price implies · The price pays for +45% free cash flow growth a year for a decade; the business has delivered −73% a year over the last three.
- Price / book
- 0.70
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 0.70
- EV / EBIToperating margin −28%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 0.73
- Free cash flow, trailing twelve months
- $4.1M
- Market capitalisation
- $1.37B
- 3-year revenue growth
- +1.7%
- 3-year free cash flow growth
- −73%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.